Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Reexamination Certificate
2005-09-07
2010-12-21
Chong, Yong S (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
C514S524000, C514S493000, C514S616000, C514S619000
Reexamination Certificate
active
07855229
ABSTRACT:
This invention provides: 1) a method of treating a subject suffering from a muscle wasting disorder; 2) a method of preventing a muscle wasting disorder in a subject; 3) a method of treating, preventing, suppressing, inhibiting or reducing muscle loss in a subject suffering from a muscle wasting disorder; 4) a method of treating, preventing, inhibiting, reducing or suppressing muscle wasting in a subject suffering from a muscle wasting disorder; and/or 5) a method of treating, preventing, inhibiting, reducing or suppressing muscle protein catabolism in a subject suffering from a muscle wasting disorder, by administering to the subject a selective androgen receptor modulator (SARM) and/or an analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, prodrug, polymorph, impurity or crystal of said SARM compound, or any combination thereof.
REFERENCES:
patent: 3239345 (1966-03-01), Hodge et al.
patent: 3865801 (1975-02-01), Chiba et al.
patent: 3875229 (1975-04-01), Gold
patent: 4036979 (1977-07-01), Asato
patent: 4139638 (1979-02-01), Neri et al.
patent: 4191775 (1980-03-01), Glen
patent: 4239776 (1980-12-01), Glen et al.
patent: 4282218 (1981-08-01), Glen et al.
patent: 4386080 (1983-05-01), Crossley et al.
patent: 4411890 (1983-10-01), Momany et al.
patent: 4465507 (1984-08-01), Konno et al.
patent: 4636505 (1987-01-01), Tucker
patent: 4880839 (1989-11-01), Tucker
patent: 4977288 (1990-12-01), Kassis et al.
patent: 5162504 (1992-11-01), Horoszewicz
patent: 5179080 (1993-01-01), Rothkopf et al.
patent: 5441868 (1995-08-01), Lin et al.
patent: 5547933 (1996-08-01), Lin et al.
patent: 5609849 (1997-03-01), Kung
patent: 5612359 (1997-03-01), Murugesan et al.
patent: 5618698 (1997-04-01), Lin et al.
patent: 5621080 (1997-04-01), Lin et al.
patent: 5656651 (1997-08-01), Sovak et al.
patent: 6019957 (2000-02-01), Miller et al.
patent: 6043265 (2000-03-01), Murugesan et al.
patent: 6071957 (2000-06-01), Miller et al.
patent: 6160011 (2000-12-01), Miller et al.
patent: 6482861 (2002-11-01), Miller et al.
patent: 6492554 (2002-12-01), Dalton et al.
patent: 6548529 (2003-04-01), Robl et al.
patent: 6569896 (2003-05-01), Dalton et al.
patent: 6777427 (2004-08-01), Miyakawa et al.
patent: 6838484 (2005-01-01), Steiner et al.
patent: 6899888 (2005-05-01), Steiner et al.
patent: 6960474 (2005-11-01), Salvati et al.
patent: 6995284 (2006-02-01), Dalton et al.
patent: 6998500 (2006-02-01), Dalton et al.
patent: 7026500 (2006-04-01), Dalton et al.
patent: 7041844 (2006-05-01), Miller et al.
patent: 7205437 (2007-04-01), Dalton et al.
patent: 7344700 (2008-03-01), Dalton et al.
patent: 7518013 (2009-04-01), Dalton et al.
patent: 7547728 (2009-06-01), Dalton et al.
patent: 2001/0012839 (2001-08-01), Miller et al.
patent: 2002/0173445 (2002-11-01), Salvati et al.
patent: 2003/0232792 (2003-12-01), Dalton et al.
patent: 2004/0014975 (2004-01-01), Dalton et al.
patent: 2004/0029913 (2004-02-01), Dalton et al.
patent: 2004/0053897 (2004-03-01), Steiner et al.
patent: 2004/0087557 (2004-05-01), Steiner et al.
patent: 2004/0087810 (2004-05-01), Dalton et al.
patent: 2004/0147489 (2004-07-01), Dalton et al.
patent: 2004/0224979 (2004-11-01), Dalton et al.
patent: 2004/0260092 (2004-12-01), Miller et al.
patent: 2004/0260108 (2004-12-01), Dalton et al.
patent: 2004/0265916 (2004-12-01), Dalton et al.
patent: 2005/0038110 (2005-02-01), Dalton et al.
patent: 2005/0137172 (2005-06-01), Dalton et al.
patent: 2006/0004042 (2006-01-01), Dalton et al.
patent: 2006/0009529 (2006-01-01), Dalton et al.
patent: 2006/0035965 (2006-02-01), Dalton et al.
patent: 2006/0111441 (2006-05-01), Dalton et al.
patent: 2006/0183931 (2006-08-01), Dalton et al.
patent: 2006/0229362 (2006-10-01), Dalton et al.
patent: 2007/0066568 (2007-03-01), Dalton et al.
patent: 2007/0123563 (2007-05-01), Dalton et al.
patent: 2007/0161608 (2007-07-01), Dalton et al.
patent: 2007/0173546 (2007-07-01), Dalton et al.
patent: 2007/0281906 (2007-12-01), Dalton et al.
patent: 2009/0088480 (2009-04-01), Dalton et al.
patent: 2002364949 (2003-06-01), None
patent: 2003216174 (2003-09-01), None
patent: 2420279 (2002-02-01), None
patent: 2477737 (2003-09-01), None
patent: 2502209 (2004-04-01), None
patent: 2502355 (2004-04-01), None
patent: 2538095 (2004-04-01), None
patent: 2529464 (2005-01-01), None
patent: 0 040 932 (1981-02-01), None
patent: 0 100 172 (1984-02-01), None
patent: 00 02 892 (1985-02-01), None
patent: 000 2892 (1985-02-01), None
patent: 0253 503 (1991-12-01), None
patent: 0253503 (1991-12-01), None
patent: 668351 (1995-08-01), None
patent: 1221439 (2002-07-01), None
patent: 1401801 (2006-11-01), None
patent: 1801140 (2007-06-01), None
patent: 1360001 (1970-03-01), None
patent: 52-128329 (1977-10-01), None
patent: 54-63047 (1980-12-01), None
patent: 59-033250 (1984-02-01), None
patent: WO 89/07110 (1989-08-01), None
patent: WO 89/07111 (1989-08-01), None
patent: WO 91/05867 (1991-05-01), None
patent: WO 93/04081 (1993-03-01), None
patent: WO 95/19770 (1995-07-01), None
patent: WO 98 05962 (1998-02-01), None
patent: WO 98/05962 (1998-02-01), None
patent: WO 98/53826 (1998-12-01), None
patent: WO 98/55153 (1998-12-01), None
patent: WO 00/01389 (2000-01-01), None
patent: WO 01/27086 (2001-04-01), None
patent: WO/01/27086 (2001-04-01), None
patent: WO 01/27622 (2001-04-01), None
patent: WO 01 27622 (2001-04-01), None
patent: WO 01 28990 (2001-04-01), None
patent: WO 01/28990 (2001-04-01), None
patent: WO 01 34563 (2001-05-01), None
patent: WO 01/34563 (2001-05-01), None
patent: WO 01/68603 (2001-09-01), None
patent: WO 02/00617 (2002-01-01), None
patent: WO 02 00617 (2002-01-01), None
patent: WO 02/16310 (2002-02-01), None
patent: WO/02/22585 (2002-03-01), None
patent: WO 02/22585 (2002-03-01), None
patent: WO 03/011302 (2003-02-01), None
patent: WO 03/049675 (2003-06-01), None
patent: WO 03/065992 (2003-08-01), None
patent: WO 03/074449 (2003-09-01), None
patent: WO/03/077919 (2003-09-01), None
patent: WO 03/077919 (2003-09-01), None
patent: WO 2004/034978 (2004-04-01), None
patent: WO 2004/035736 (2004-04-01), None
patent: WO 2005/000794 (2005-01-01), None
patent: WO 2005/060647 (2005-07-01), None
U.S. Appl. No. 09/935,044, filed Aug. 23, 2001, Dalton et al.
U.S. Appl. No. 09/935,045, filed Aug. 23, 2001, Dalton et al.
U.S. Appl. No. 09/644,970, filed Aug. 2, 2000, Dalton et al.
Negro-Vilar, A. (1999) “Selective androgen receptor modulators (SARMs): a novel approach to androgen therapy for the new illennium.” J. Clin. Endocrin Metabol. 84: 3459-3462.
Campfield et al., 1995, “Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks”Science269:546-549.
Considine et al., 1995, “Evidence against either a premature stop codon or the absence of obese gene mRNA in human obesity,” J. Clin. Invest. 95:2986-2988.
Grundy, 1990,Disease-a-Month36:645-696.
Halaas et al., 1995, “Weight-reducing effects of the plasma protein encoded by the obese gene.”Science269:543-546.
Hamilton et al., 1995, “Increased obese mRNA expression in omental fat cells from massively obese humans.” Nature Med. 1:953.
Lonnquist et al., 1995, Nature Med. 1:950.
Matsumoto, 1994, “Hormonal therapy of male hypogonadism” Endocrinol. Met. Clin. N. Am. 23:857-75.
Pelleymounter et al., 1995, “Effects of the obese gene product on body weight regulation in ob/ob mice.”Science269:540-543.
Singh et al., 2003, “Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway.”Endocrinology, 144(11):5081-8.
Sefton, 1987, “Implantable pumps.” CRC Crit. Ref. Biomed. Eng. 14:201.
Eliason et al., “High Throughput Fluorescence Polarization-Based Screening Assays for the Identification of Novel Nuclear Receptor Ligands,” Abstracts of Papers, 223rd ACS National Meeting, Orlando, FL, United States, (2002), Apr. 7, 2002.
Berger et al., “Concepts and limitations in th
Dalton James T.
Miller Duane D.
Steiner Mitchell S.
Veverka Karen A.
Chong Yong S
Cohen Mark S.
Pearl Cohen Zedek Latzer LLP
University of Tennessee Research Foundation
LandOfFree
Treating wasting disorders with selective androgen receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treating wasting disorders with selective androgen receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treating wasting disorders with selective androgen receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4224828